Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and has a 5-year survival rate of 6% was reported in year 2011 worldwide ([@b1-ol-0-0-11097]). Although advances have been made in the prevention of PDAC as well as in surgical approaches and adjuvant therapy, the mortality rates in patients with PDAC remain high ([@b2-ol-0-0-11097],[@b3-ol-0-0-11097]). Several risk factors such as smoking ([@b4-ol-0-0-11097]), diabetes ([@b5-ol-0-0-11097]) and hereditary pancreatitis ([@b6-ol-0-0-11097]) have been identified. However, tissue biomarkers or gene signatures for the prognosis prediction of PDAC have not been well established ([@b7-ol-0-0-11097]). The identification of a reliable prognostic genetic determinant in PDAC is an area of ongoing research and may aid in individualized risk assessment and treatment decision-making. Furthermore, biomarkers might present novel therapeutic targets for the treatment of PDAC.

The inflammatory process is a key mediator of pancreatic cancer development and progression, and patients with chronic pancreatitis have an increased risk of developing pancreatic cancer ([@b8-ol-0-0-11097]--[@b10-ol-0-0-11097]). Trypsin-1, the main trypsinogen secreted by the pancreas and encoded by the serine protease 1 gene (*PRSS1*), has attracted attention in the field of PDAC research ([@b11-ol-0-0-11097]). Previous studies revealed that mutations in *PRSS1* are associated with autoimmune ([@b12-ol-0-0-11097]) and chronic pancreatitis ([@b13-ol-0-0-11097]). Progressive mutation accumulation and clonal expansion, however, are required for the development of invasive PDAC ([@b11-ol-0-0-11097]). Mutations in the *PRSS1* gene have been reported to be associated with an increased incidence of PDAC ([@b10-ol-0-0-11097],[@b14-ol-0-0-11097]--[@b16-ol-0-0-11097]). The −409 C/T *PRSS1* genotype has been found to protect against the development of pancreatic cancer in the Han Chinese population ([@b17-ol-0-0-11097]); however, the prognostic value of the aforementioned *PRSS1* genotype in patients with PDAC remains poorly understood.

The aim of the current study was to investigate the association of the −409 C/T *PRSS1* genotype with the clinicopathological characteristics and prognosis of patients with PDAC.

Materials and methods
=====================

### Patient recruitment

Patients with PDAC from The First Affiliated Hospital of Fujian Medical University (Fuzhou, China) were enrolled between 2015 and 2017. The inclusion criteria were as follows: i) Patients with pathologically confirmed PDAC diagnosis; ii) patients who had received radical resection; and iii) patients who had not received any preoperative therapy (including radiotherapy, chemotherapy or targeted therapy). Patients with any comorbid or previous malignancies were excluded from the analysis. A total of 124 patients were eligible for inclusion in the current study, including 76 males and 48 females, with a median age of 60 years (range, 28--86 years).

The present study was performed in accordance with the ethical principles described in the Declaration of Helsinki and was approved by the Ethics and Research Committee of The First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from all patients.

### Genotype analysis

Peripheral blood samples were collected from the peripheral vein. Following anticoagulation with EDTA and centrifugation in 1,509 × g at 4°C for 5 min, genomic DNA was extracted from each patient using a TIANamp Blood DNA kit (Tiangen Biotech Co., Ltd.), and was stored at −20°C. Following the manufacturer\'s instructions, the full-length *PRSS1* gene was amplified, and following purification, sequencing was performed and analyzed by Sangon Biotech Co., Ltd. The 50 µl reaction mixture used to generate the fragments contained 200 ng genomic DNA, 10 mmol/l Tris-hydrochloric acid (pH 9.0), 50 mmol/l potassium chloride, 0.1% triton, 2 mmol/l magnesium chloride, 0.25 mmol/l deoxynucleotide mix, 100 ng upstream primer, 100 ng downstream primer and 3.0 units of Taq DNA-polymerase (Sangon Biotech Co., Ltd). The thermocycling conditions included an initial denaturing step at 95°C for 5 min, followed by 30 cycles at 95°C for 30 sec, 55°C for 30 sec and 72°C for 1 min, followed by a final extension step at 72°C for 10 min. PCR products were subsequently run on an 1% agarose gel in 1X TAE buffer and purified by a MinElute Gel Extraction kit (Qiagen GmbH). Following the manufacturer\'s instructions, a Perkin-Elmer Big Dye Sequencing kit (PerkinElmer, Inc.) and an ABI PRISM7700 sequencer (PerkinElmer, Inc.) were used for sequencing. The *PRSS1* primers as follows: Forward, 5′-GGTCCTGGGTCTCATACCTT-3′ and reverse, 5′-GGGTAGGAGGCTTCACACTT-3′.

### Statistical analysis

Statistical analysis was performed using SPSS software (version 20.0; IBM Corp.). Data are expressed as means ± standard deviation or number and percentage as appropriate. The association between the *PRSS1* genotype and the clinicopathological parameters of the patients was evaluated using the c^2^ or Fisher\'s exact tests as appropriate. The overall survival (OS) was defined as the time period between surgery and mortality or the last follow-up. Survival outcomes were evaluated by the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazard regression model was used for univariate and multivariate analyses of prognosis predictive factors. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### PRSS1 genotype in PDAC

In the current study, PCR was used to determine the *PRSS1* genotype in the enrolled patients. The results revealed that multiple loci contained one of three genotypes: C/C, C/T or T/T ([Fig. 1](#f1-ol-0-0-11097){ref-type="fig"}), which is similar to results that have been previously reported ([@b18-ol-0-0-11097],[@b19-ol-0-0-11097]). Moreover, 58 patients with PDAC (43.75%) had the T/C genotype ([Table I](#tI-ol-0-0-11097){ref-type="table"}), which was regarded as a mutation.

### Associations between the PRSS1 genotype and clinicopathological characteristics

As shown in [Table I](#tI-ol-0-0-11097){ref-type="table"}, the T/C *PRSS1* genotype was associated with larger tumor sizes (P=0.027), higher tumor-node-metastasis (TNM) stages (P=0.041) and higher levels of serum carcinoembryonic antigen (CEA) (P=0.038) compared with the C/C or T/T *PRSS1* genotypes. However, no associations between the T/C *PRSS1* genotype and age, sex, tumor location, serum carbohydrate antigen (CA) 19-9 and 12-5 levels, perineural invasion or lymphovascular invasion were observed (all P\>0.05).

### Prognostic impact of the PRSS1 genotype

The possible association of the *PRSS1* genotype with OS in patients with PDAC was investigated using Kaplan-Meier survival curves and log-rank tests. It was revealed that following a median follow-up period of 19 months, the T/C *PRSS1* genotype was associated with a worse OS time compared with the T/T and C/C *PRSS1* genotypes (P=0.037; [Fig. 2](#f2-ol-0-0-11097){ref-type="fig"}).

### Univariate and multivariate analyses of predictive factors of OS

Univariate analysis revealed that surgical type (P=0.032), serum CA19-9 level (P=0.001), serum CEA level (P=0.034), TNM stage III (P=0.005), TNM stage IV (P\<0.001), and *PRSS1* genotype (P=0.002) were significantly associated with the OS time of patients with PDAC ([Table II](#tII-ol-0-0-11097){ref-type="table"}).

A multivariate analysis using the Cox regression model was subsequently performed, and the results revealed that the serum CA19-9 level \[hazard ratio (HR)=1.001; P=0.001\], TNM stage III (HR=2.078; P=0.031), TNM stage IV (HR=3.090; P=0.041), and *PRSS1* genotype (HR=2.196; P=0.002) were independent predictors of the OS time in patients with PDAC ([Table III](#tIII-ol-0-0-11097){ref-type="table"}).

Discussion
==========

The current study revealed that the T/C *PRSS1* genotype was statistically associated with larger tumor size and higher TNM stage compared with other genotypes. To the best of the authors\' knowledge, the present study was the first to demonstrate that the T/C *PRSS1* genotype was associated with poor OS, and that the aforementioned genotype may serve as an independent prognostic factor of OS in patients with PDAC, together with factors including serum CA19-9 level and TNM stage.

Previous studies revealed that the processes of genotype accumulation and clonal expansion are required for the development of invasive PDAC ([@b11-ol-0-0-11097],[@b16-ol-0-0-11097],[@b20-ol-0-0-11097]). Many efforts have been made to identify gene mutations associated with pancreatic cancer, including mutL homolog 1 and PMS1 homolog 1, mismatch repair system component ([@b21-ol-0-0-11097]), and BRCA1/2 DNA repair ([@b22-ol-0-0-11097]). Increasing numbers of studies have demonstrated that mutations in the *PRSS1* gene are associated with an increased incidence of PDAC ([@b10-ol-0-0-11097],[@b14-ol-0-0-11097]--[@b16-ol-0-0-11097]). Furthermore, the −409 C/T *PRSS1* genotype was found to exert a protective effective against pancreatic cancer in the Han Chinese population ([@b17-ol-0-0-11097]). *PRSS1* encodes trypsin-1, the main trypsinogen enzyme secreted by the pancreas. *PRSS1* mutations have been associated with increased trypsin-1 serum levels as well as the trypsin and α1-antitrypsin imbalance observed in patients with pancreatic cancer, which may alter the pancreatic microenvironment and increase immunological escape and clonal proliferation of pancreatic cancer cells ([@b19-ol-0-0-11097]). However, the clinicopathological and prognostic significance of *PRSS1* mutations in patients with PDAC remains unclear.

*PRSS1* mutations have been previously shown to be associated with autoimmune ([@b12-ol-0-0-11097]) and chronic pancreatitis ([@b13-ol-0-0-11097]). Additionally, the mean serum trypsin level was increased in patients with pancreatic cancer compared with healthy controls ([@b19-ol-0-0-11097]). While the *PRSS1* gene is not currently considered to be an oncogene, tumor-suppressor gene or genome-maintenance gene, *PRSS1* genotypes were strongly correlated with the trypsin and α1-antitrypsin imbalance in patients with pancreatic cancer ([@b13-ol-0-0-11097]).

Traditional prognostic factors, including serum CA19-9 level and TNM stage, were identified as independent prognostic factors of OS in patients with PDAC in the current study, similarly to previously published studies ([@b7-ol-0-0-11097],[@b23-ol-0-0-11097]). In the current study, the T/C *PRSS1* genotype indicated a poor prognosis and a shorter OS time in patients with PDAC, as demonstrated by the Kaplan-Meier method. Furthermore, associations between the *PRSS1* genotype and clinicopathological parameters such as large tumor size and higher TNM stage were identified in the current study, suggesting that the *PRSS1* genotype may be involved in the progression and aggressiveness of pancreatic cancer. Moreover, by using univariate and Cox regression analysis, the results obtained in the current study demonstrated that the *PRSS1* genotype was an independent prognostic factor of OS in patients with PDAC. The *PRSS1* genotype may aid the selection of treatment plans and the identification of patients who may benefit from additional adjuvant therapy.

The current study had a number of limitations. Firstly, the present study was a single-centre retrospective study. Secondly, a limited sample size was included in the current study. Thirdly, patients with unresectable PDAC were not included in the current study due to insufficient data. Finally, all the patients enrolled in the current study were of Chinese descent, therefore the association between the mutation status of *PRSS1* and prognosis of patients of different ethnicities was not investigated. Nevertheless, the current study contributed to the understanding of the association between the *PRSS1* genotype and prognosis of patients with PDAC.

In conclusion, the current study demonstrated that the T/C *PRSS1* genotype was associated with large tumor size, higher TNM stage and poor OS compared with other genotypes. The *PRSS1* genotype, together with other factors including serum CA19-9 level and TNM stage, may therefore be used as an independent prognostic factor of OS in patients with PADC.
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###### 

Prognostic impact of *PRSS1* genotype on the prognosis of patients with pancreatic ductal adenocarcinoma.

                               *PRSS1* genotype                 
  ---------------------------- ------------------ ------------- -------
  Age, years (mean ± SD)       61.5±12.7          59.7±10.3     0.253
  Sex, n (%)                                                    0.534
    Male                       36 (64.3)          40 (58.8)     
    Female                     20 (35.7)          28 (41.2)     
  Tumor size, cm (mean ± SD)   3.9±2.6            3.2±1.5       0.027
  Tumor location, n (%)                                         0.688
    Head                       41 (73.2)          53 (77.9)     
    Body and tail              15 (26.8)          15 (22.1)     
  CEA, ng/ml (mean ± SD)       7.7±15.1           15.9±48.7     0.038
  CA19-9, U/ml (mean ± SD)     291.6±375.9        302.2±361.5   0.717
  CA125, U/ml (mean ± SD)      50.1±89.3          45.7±78.7     0.460
  TNM stage, n (%)                                              0.041
    I                          11 (19.6)          19 (27.9)     
    II                         13 (23.2)          27 (39.7)     
    III                        27 (48.2)          20 (29.4)     
    IV                         5 (8.9)            2 (2.9)       
  Perineural invasion, n (%)                                    0.874
    Yes                        19 (33.9)          24 (35.3)     
    No                         37 (66.1)          44 (64.7)     
  Vascular invasion, n (%)                                      0.442
    Yes                        43 (76.8)          56 (82.4)     
    No                         13 (23.2)          12 (17.6)     

*PRSS1*, serine protease 1; TNM, tumor-node-metastasis; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.

###### 

Univariate analysis of factors affecting the overall survival time in patients with pancreatic ductal adenocarcinoma.

                                                      Univariate analysis                   
  --------------------------------------------------- --------------------- --------------- ---------
  Sex (male vs. female)                               0.785                 0.510--1.208    0.271
  Age                                                 1.016                 0.996--1.036    0.113
  Surgery type (Whipple surgery vs. pancreatectomy)   1.626                 1.042--2.537    0.032
  Resection margin (yes vs. no)                       1.049                 0.476--2.315    0.905
  Tumor size                                          1.155                 1.038--1.285    0.008
  Serum CA19-9 level                                  1.001                 1.000--1.002    0.001
  Serum CEA level                                     1.007                 1.001--1.014    0.034
  Serum CA125 level                                   1.001                 0.999--1.004    0.194
  TNM stage                                                                                 
    I                                                 Reference value                       0.001
    II vs. I                                          1.691                 0.931- 3.072    0.085
    III vs. I                                         2.257                 1.272--4.005    0.005
    IV vs. I                                          5.320                 2.186--12.947   \<0.001
  Perineural invasion (yes vs. no)                    1.303                 0.841--2.020    0.237
  Vascular invasion (yes vs. no)                      1.487                 0.921--2.398    0.104
  *PRSS1* genotype (T/C vs. C/C or T/T)               1.961                 1.293--2.973    0.002

HR, hazard ratio; CEA, carcinoembryonic antigen; CA, carbohydrate antigen, *PRSS1*, serine protease 1 gene.

###### 

Multivariate analysis of factors affecting the overall survival time in patients with pancreatic ductal adenocarcinoma.

  Variable                                            Regression coefficient   SE        HR      95% CI         P-value
  --------------------------------------------------- ------------------------ --------- ------- -------------- ---------
  Surgery type (Whipple surgery vs. pancreatectomy)   −0.009                   0.274     0.991   0.579--1.695   0.973
  Tumor size                                          0.081                    0.067     1.085   0.952--1.236   0.223
  Serum CA19-9 level                                  0.001                    \<0.001   1.001   1.000--1.002   0.001
  Serum CEA level                                     0.006                    0.005     1.006   0.996--1.016   0.230
  TNM stage                                                                                                     
    I                                                 Reference value                                           0.110
    II vs. I                                          0.613                    0.345     1.847   0.938--3.634   0.076
    III vs. I                                         0.731                    0.339     2.078   1.068--4.041   0.031
    IV vs. I                                          1.128                    0.551     3.090   1.049--9.104   0.041
  *PRSS1* genotype (T/C vs. C/C or T/T)               0.786                    0.249     2.196   1.347--3.580   0.002

SE, standard error; HR, hazard ratio; CEA, carcinoembryonic antigen; CA, carbohydrate antigen, *PRSS1*, serine protease 1 gene.
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